FDA Inks Class II Designation For Embryo Viability Tests
This article was originally published in The Gray Sheet
Executive Summary
The agency set a class II with special controls designation for assisted reproduction embryo image assessment systems in a Feb. 26 final order, following the de novo decision for Auxogyn’s Eeva system last summer.
You may also be interested in...
Testing For Toxicity In Fertility Treatment Technologies
US regulators are proposing makers of fertility assistant devices first test their products on mice embryos in the lab to better understand any potential toxicity risk to human embryos and the viability of the fetus.
EU Extends Provisions For Ensuring Post-Brexit Flow Of Medicines
Proposals for averting medicines supply disruptions caused by Brexit in Northern Ireland and three EU markets are about to be discussed by EU legislators.
Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.